For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 1,113,105 | |||
| General and administrative | 5,731,682 | |||
| Impairment of in-process research and development | 18,647,903 | |||
| Total operating expenses | 25,492,690 | |||
| Loss from operations | -25,492,690 | |||
| Interest expense | -513,209 | |||
| Change in fair value of equity payable | -201,862 | |||
| Pre-tax net loss | -25,804,037 | |||
| Income tax benefit (provision) | -851,659 | |||
| Net loss | -24,952,378 | |||
| Basic EPS | -4.18 | |||
| Diluted EPS | -4.18 | |||
| Basic Average Shares | 5,963,943 | |||
| Diluted Average Shares | 5,963,943 | |||
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)